159 related articles for article (PubMed ID: 31353059)
21. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
[TBL] [Abstract][Full Text] [Related]
23. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
24. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
25. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Oliveira ML; Akkapeddi P; Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2019 Jan; 71():88-96. PubMed ID: 30249539
[TBL] [Abstract][Full Text] [Related]
26. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
27. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
[TBL] [Abstract][Full Text] [Related]
28. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
29. Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases.
Xu W; Chen S; Wang X; Tanaka S; Onda K; Sugiyama K; Yamada H; Hirano T
Pharmacol Ther; 2021 Jan; 217():107659. PubMed ID: 32800789
[TBL] [Abstract][Full Text] [Related]
30. From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia.
Oliveira ML; Akkapeddi P; Alcobia I; Almeida AR; Cardoso BA; Fragoso R; Serafim TL; Barata JT
Cell Signal; 2017 Oct; 38():10-25. PubMed ID: 28645565
[TBL] [Abstract][Full Text] [Related]
31. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
32. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
33. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
34. Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia.
Goossens S; Van Vlierberghe P
PLoS Med; 2016 Dec; 13(12):e1002208. PubMed ID: 27997538
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.
Beesley AH; Firth MJ; Ford J; Weller RE; Freitas JR; Perera KU; Kees UR
Br J Cancer; 2009 Jun; 100(12):1926-36. PubMed ID: 19436302
[TBL] [Abstract][Full Text] [Related]
36. Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.
Bongiovanni D; Saccomani V; Piovan E
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28872614
[TBL] [Abstract][Full Text] [Related]
37. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Naik J; Themeli M; de Jong-Korlaar R; Ruiter RWJ; Poddighe PJ; Yuan H; de Bruijn JD; Ossenkoppele GJ; Zweegman S; Smit L; Mutis T; Martens ACM; van de Donk NWCJ; Groen RWJ
Haematologica; 2019 Mar; 104(3):e100-e103. PubMed ID: 30190344
[No Abstract] [Full Text] [Related]
38. TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Zhao Q; Zhao S; Li J; Zhang H; Qian C; Wang H; Liu J; Zhao Y
Biomed Pharmacother; 2019 Jan; 109():1640-1649. PubMed ID: 30551418
[TBL] [Abstract][Full Text] [Related]
39. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
40. Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia.
Jung HJ; Han EH; Jang IK; Yoon SH; Park JE
Anticancer Res; 2019 Nov; 39(11):6165-6173. PubMed ID: 31704844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
